Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

West Pharmaceutical Services Breach: Protecting Pharma’s Data and Market Advantage

West Pharmaceutical Services cyber‑breach reveals the growing risk to pharma data security—why operational resilience, IP protection, and strategic M&A matter for industry survival.

Lisa Martinez

03/08/2026, 03:49

5 minutes to read

Pfizer’s Q4 Earnings: Navigating Patent Cliffs, Biosimilar Growth, and Strategic M&A for Long‑Term Success

Explore how Pfizer’s latest earnings, patent cliffs, and biosimilar strategy shape its growth outlook in today’s pharma market.

Lisa Martinez

02/08/2026, 18:23

4 minutes to read

Haleon plc Confirms Regulatory Consistency & Strategic Focus in July 2026 Filing

Haleon plc’s July 30 2026 filing confirms consistent U.S. reporting, steady H1 revenue, and a focused consumer‑health strategy that balances patent protection, M&A opportunities, and disciplined R&D to sustain growth.

Lisa Martinez

02/08/2026, 08:08

5 minutes to read

Takeda Q1 2026: Strong Operating Margins, Net Profit Dip, & Strategic M&A Outlook

Takeda Q1 2026: revenue up 5.4% despite net‑profit dip, driven by yen gain and flagship drugs, while operating margin grows and pipeline strength keeps growth prospects strong.

Lisa Martinez

01/08/2026, 15:22

4 minutes to read

How Novo Nordisk Navigates GLP‑1 Market Shifts and Patent Cliffs for Future Growth

Investors weigh Novo Nordisk’s €45 share price and GLP‑1 obesity strategy, noting slowing uptake of Wegovy and Zepbound, new combination therapies, and a 2030‑2033 patent cliff that could reshape market dynamics.

Lisa Martinez

31/07/2026, 23:27

4 minutes to read

Shionogi’s Long‑Acting HIV Strategy: Market Advantage, Patent Play, and Growth Paths

Explore how Shionogi & Co. Ltd’s long‑acting HIV therapies gain market share, leverage real‑world data, and navigate patent cliffs for future growth.

Lisa Martinez

31/07/2026, 08:28

4 minutes to read

How Piramal Pharma’s Q1‑2026 Results Showcase Strong Revenue Growth and Operational Gains

First‑quarter 2026: Piramal Pharma shows steady revenue growth, higher EBITDA, and strong FDA compliance, positioning it for continued success in CDMO, generics, and consumer‑healthcare markets.

Lisa Martinez

31/07/2026, 02:54

4 minutes to read

Pfizer‑BioNTech Secures EU XFG COVID‑19 Vaccine Deal, Boosting Market Access and Revenue Potential

Explore how Pfizer‑BioNTech’s EU XFG‑variant COVID‑19 vaccine secures market access, drives €4.2 bn revenue, and navigates patent cliffs and supply‑chain risks.

Lisa Martinez

30/07/2026, 22:12

4 minutes to read

How Novo Nordisk’s Wegovy and Cell‑Based Platform Drive 2025 Growth & Mitigate Patent Cliffs

How Novo Nordisk’s Wegovy growth, cell‑based platform, and legal challenges shape its future in obesity and diabetes markets.

Lisa Martinez

30/07/2026, 22:02

4 minutes to read

J&J’s $1.2B Firefly Buy & Sail Biomed Collaboration Power‑Up Oncology & Immunology Growth

Johnson & Johnson’s $1.2 billion Firefly Bio deal and Sail Biomedicines partnership boost oncology and CAR‑T portfolios, offering patent protection and high‑growth market access.

Lisa Martinez

30/07/2026, 21:21

5 minutes to read

Newer articles